Sending a Message: FDA Leadership Responds to McNeil Recall
This article was originally published in RPM Report
Executive Summary
Deputy Commissioner Josh Sharfstein told a House committee investigating J&J's consumer products recall that the agency is "sending a message to industry" that it is getting tougher on manufacturing compliance. Here is his prepared testimony.
You may also be interested in...
No Walk in the Park: FDA Talks Tough about Executive Accountability
If history is any guide, FDA will soon start showing its teeth as a regulatory enforcement agency. That makes this a good time for executives to refresh their memory about the doctrine of strict liability for FD&C Act violations-and to ponder the implications of the Department of Justice's recent use of the so-called Park doctrine against three top execs at Purdue Pharma.
Fostering Trust at FDA
Joshua Sharfstein left his post as principle deputy commissioner of the Food & Drug Administration in January, leaving behind a short but productive legacy of increasing the level of transparency at FDA. Just before he left to become Maryland’s Secretary of Health and Mental Hygiene, he discussed transparency at the FDA/CMS Summit for Biopharmaceutical Executives. Here are excerpts from Sharfstein’s speech.